参考文献/References:
[1] Lu HC,Mackie K.An introduction to the endogenous cannabinoid system[J].Biol Psychiatry,2016,79(7):516-525.
[2] Bisogno T,Melck D,Bobrov MYu,et al.N-acyl-dopamines: novel synthetic CB(1)cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo[J].Biochem J,2000,5(Pt):3817-3824.
[3] Ji D,Jang CG,Lee S.A sensitive and accurate quantitative method to determine N-arachidonoyldopamine and N-oleoyldopamine in the mouse striatum using column-switching LC-MS-MS:use of a surrogate matrix to quantify endogenous compounds[J].Anal Bioanal Chem,2014,406(18):4491-4499.
[4] Balvers MG,Verhoeckx KC,Witkamp RF.Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry[J].J Chromatogr B Analyt Technol Biomed Life Sci,2009,877(14/15):1583-1590.
[5] Thomas A,Hopfgartner G,Giroud C,et al.Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography[J].Rapid Commun Mass Spectrom,2009,23(5):629-638.
[6] Huang SM,Bisogno T,Trevisani M,et al.An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors[J].Proc Natl Acad Sci USA,2002,99(12):8400-8405.
[7] Hu SS,Bradshaw HB,Benton VM,et al.The biosynthesis of N-arachidonoyl dopamine(NADA),a putative endocannabinoid and endovanilloid,via conjugation of arachidonic acid with dopamine[J].Prostaglandins Leukot Essent Fatty Acids,2009,81(4):291-301.
[8] Rimmerman N,Bradshaw HB,Basnet A,et al.Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors[J].Prostaglandins Other Lipid Mediat,2009,88(1/2):10-17.
[9] Puighermanal E,Marsicano G,Busquets-Garcia A,et al.Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling[J].Nat Neurosci,2009,12(9):1152-1158.
[10] Fernandez-Ruiz J,Garcia C,Sagredo O,et al.The endocannabinoid system as a target for the treatment of neuronal damage[J].Expert Opin Ther Targets,2010,14(4):387-404.
[11] Marinelli S,Di Marzo V,Florenzano F,et al.N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors[J].Neuropsychopharmacology,2007,32(2):298-308.
[12] Stelt MD.Di marzo V.endovanilloids.putative endogenous ligands of transient receptor potential vanilloid 1 channels[J].Eur J Biochem,2004,271(10):1827-1834.
[13] Mogg AJ,Mill CE,Folly EA,et al.Altered pharmacology of native rodent spinal cord TRPV1 after phosphorylation[J].Br J Pharmacol,2013,168(4):1015-1029.
[14] Cavanaugh DJ,Chesler AT,Braz JM,et al.Restriction of transient receptor potential vanilloid-1 to the peptidergic subset of primary afferent neurons follows its developmental downregulation in nonpeptidergic neurons[J].J Neurosci,2011,31(28):10119-10127.
[15] Schumacher MA.Transient receptor potential channels in pain and inflammation:therapeutic opportunities[J].Pain Pract,2010,10(3):185-200.
[16] Szallasi A,Cortright DN,Blum CA,et al.The vanilloid receptor TRPV1: 10 years from Channel cloning to antagonist proof-of-concept[J].Nat Rev Drug Discov,2007,6(5):357-372.
[17] Islam MT.Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders[J].Neurol Res,2017,39(1):73-82.
[18] Bobrov MY,Lizhin AA,Andrianova EL,et al.Antioxidant and neuroprotective properties of N-arachidonoyldopamine[J].Neurosci Lett,2008,431(1):6-11.
[19] Novosadova EV,Arsenyeva EL,Manuilova ES,et al.Neuroprotective properties of endocannabinoids N-Arachidonoyl dopamine and N-Docosahexaenoyl dopamine examined in neuronal precursors derived from human pluripotent stem cells[J].Biochemistry(Mosc),2017,82(11):1367-1372.
[20] Sukhanova IA,Sebentsova EA,Khukhareva DD,et al.Early-life N-arachidonoyl-dopamine exposure increases antioxidant capacity of the brain tissues and reduces functional deficits after neonatal hypoxia in rats[J].Int J Dev Neurosci,2019,18:787-818.
[21] Navarrete CM,Fiebich BL,De Vinuesa A,et al.Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells[J].J Neurochem,2009,109(2):452-464.
[22] Carmen-M N,Pérez M,De Vinuesa A,et al.Endogenous N-acyl-dopamines induce COX-2 expression in brain endothelial cells by stabilizing mRNA through a p38 dependent pathway[J].Biochem Pharmacol,2010,79(12):1805-1814.
[23] Wilhelmsen K,Khakpour S,Tran A,et al.The endocannabinoid/endovanilloid N-arachidonoyl dopamine(NADA)and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells[J].J Biol Chem,2014,289(19):13079-13100.
[24] Sancho R,Macho A,De La Vega L,et al.Immunosuppressive activity of endovanilloids:N-arachidonoyl-dopamine inhibits activation of the NF-kappa B,NFAT,and activator protein 1 signaling pathways[J].J Immunol,2004,172(4):2341-2351.
[25] Nagamoto-Combs K,Combs CK.Microglial phenotype is regulated by activity of the transcription factor,NFAT(nuclear factor of activated T cells)[J].J Neurosci,2010,30(28):9641-9646.
[26] Yoo JM,Park ES,Kim MR,et al.Inhibitory effect of N-Acyl dopamines on IgE-mediated allergic response in RBL-2H3 cells[J].Lipids,2013,48(4):383-393.
[27] Grabiec U,Koch M,Kallendrusch S,et al.The endocannabinoid N-arachidonoyldopamine(NADA)exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1(CB(1))[J].Neuropharmacology,2012,62(4):1797-1807.
[28] Bjorklund E,Noren E,Nilsson J,et al.Inhibition of monoacylglycerol lipase by troglitazone,N-arachidonoyl dopamine and the irreversible inhibitor JZL184:comparison of two different assays[J].Br J Pharmacol,2010,161(7):1512-1526.
[29] Speer RE,Karuppagounder SS,Basso M,et al.Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators:From ferroptosis to stroke[J].Free Radic Biol Med,2013,62:6226-6236.
[30] Soler-Torronteras R,Lara-Chica M,Garcia V,et al.Hypoximimetic activity of N-acyl-dopamines.N-arachidonoyl-dopamine stabilizes HIF-1alpha protein through a SIAH2-dependent pathway[J].Biochim Biophys Acta,2014,1843(11):2730-2743.